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MMPThis study determined the role of MMP9/gelatinase B during the migration onset of Neural Crest Cells (NCC)
in avian embryos. NCC are neuroepithelial progenitors that convert into mesenchyme and migrate along de-
ﬁned paths throughout the embryo. To engage in migration, NCC loose cell contacts, detach from the neural
tube and invade the surrounding environment. Multiple signals and transcription factors that regulate these
events have been identiﬁed. Nevertheless, little is known regarding effectors that act downstream to execute
the actual NCC migration. Matrix metalloproteinases (MMPs) compose a large family of enzymes whose prin-
cipal substrates are basement membranes, adhesion proteins and the extracellular matrix (ECM) compo-
nents. A major subgroup of MMPs, the gelatinases (MMP9 and 2) are central to many adult physiological
and pathological processes, such as tumor metastasis and angiogenesis, in which cell–cell and cell–matrix
contacts are degraded to allow migration. As NCC undergo similar processes during development, we hy-
pothesized that MMP9 may also promote the migration of NCC.
MMP9 was found to be expressed in delaminating and migrating NCC of both cranial and trunk axial levels.
Blocking MMP9 resulted in a dramatic inhibition of NCC delamination and migration, without perturbing
speciﬁcation or survival. This inhibition occurred at regions containing both premigratory and migrating
cells, indicative for the central role of MMP9 in executing the detachment of NCC from the neural tube as
well as their migration. Conversely, excess MMP9 enhanced mesenchymalization and delamination of NCC
and accelerated progenitors to undergo precocious migration. Examination of the mechanistic activity of
MMP9 revealed its capability to degrade the adhesion molecule N-cadherin as well as the basement-
membrane protein laminin within or around NCC, respectively. Altogether, our study reveals MMP9 as a
novel effector which is required for NCC delamination and migration.
© 2012 Elsevier Inc. All rights reserved.Introduction
Neural crest cells (NCC) are a discrete cell-population that arises
from the dorsal neural tube and migrate along deﬁned pathways
throughout the embryo. NCC give rise to a variety of derivatives in-
cluding sensory neurons/ganglia, Schwann cells, pigments and endo-
crine cells, as well as generate most of the craniofacial cartilage and
bones (for reviews see Barembaum and Bronner-Fraser, 2005; Erickson
and Reedy, 1998; Kalcheim and Burstyn-Cohen, 2005; Le-Douarin and
Kalcheim, 1999). Prior to their migration, NCC constitute an integral
part of the neural tube, whereas subsequently, they undergo
epithelial-to-mesenchymal transition (EMT) and detach from the neu-
roepithelium as mesenchymal cells (reviewed in Le-Douarin and
Kalcheim, 1999; Raible, 2006; Taylor and LaBonne, 2007). This dramatic
process requires changes in cellular and extra-cellular behaviors such as
the breakdown of the basal lamina around the dorsal neural tube,nfeld).
rights reserved.switches in expression of cell–cell and cell–matrix adhesion molecules,
modiﬁcation in cytoskeleton assembly, development ofmotility and ap-
pearance of guidance cues (Barembaum and Bronner-Fraser, 2005;
Gammill and Roffers-Agarwal, 2010; Kulesa and Gammill, 2010;
Le-Douarin and Kalcheim, 1999; Trainor, 2005).
A central signal that coordinates the onset of NCC migration is the
bone morphogenetic protein (BMP). An interplay between BMP4 and
its inhibitor noggin in the dorsal neural tube determines the levels of
BMP signals required for NCC delamination by stimulating Wnt sig-
naling and N-cadherin cleavage (Burstyn-Cohen and Kalcheim,
2002; Burstyn-Cohen et al., 2004; Sela-Donenfeld and Kalcheim,
1999, 2000, 2002; Shoval et al., 2007). Recently, gradients of meso-
dermal retinoic acid and FGF were also found to regulate the timing
of NCC migration by modulating the activity of Wnt, BMP and noggin
(Martinez-Morales et al., 2011). A complex network of DNA binding
proteins, such as Sox8–10, Snail and Foxd3, also orchestrates NCC de-
lamination intrinsically (Basch and Bronner-Fraser, 2006; Cano et al.,
2000; Cheung et al., 2005; Gammill and Bronner-Fraser, 2003; Trainor,
2005). In addition, modulations in adhesion molecules, ADAM prote-
ases and small GTPases are also essential for this process (Alfandari et
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Groysman et al., 2008; Jhingory et al., 2010; Nakagawa and Takeichi,
1998; Newgreen and Minichiello, 1995; Shoval et al., 2007; Wei et
al., 2010). Yet, soluble effectors that should act downstream to these
pathways to execute the actual detachment and migration of NCC
by modifying cell–cell and cell–matrix interactions, are much less
known (Erickson and Reedy, 1998; Kalcheim, 2000; Radisky, 2005;
Taylor and LaBonne, 2007; Thiery et al., 1988).
Proteolysis is a major process leading to dramatic changes in cell
migration and contacts by affecting cell–cell/cell–extracellular matrix
(ECM) adherence, ECM and basement membrane degradation, releas-
ing of bioactive fragments, sequestering of growth factors and shed-
ding of cell-surface proteins (Mott and Werb, 2004). The matrix
metalloproteinases (MMPs) are a large family of secreted enzymes
able to degrade structural proteins of the ECM and basal lamina in dif-
ferent physiological and pathological contexts (Hasky-Negev et al.,
2008; Nelson et al., 2000; Sternlicht and Werb, 2001). 25 members
have been identiﬁed in vertebrates (Lohi et al., 2001; Nagase and
Woessner, 1999) and grouped into 4 main subfamilies, according to
their structure and substrate speciﬁcity; collagenases, gelatinases,
stromelysins and the membrane-type MMPs. Each of these has a dis-
tinct, but often overlapping, substrate speciﬁcity that together can
cleave numerous substrates, including virtually all ECM proteins
(Sternlicht andWerb, 2001). Several MMPs were also shown to digest
cadherins and integrins, leading also to changes in cell–cell and cell–
ECM adherence. Moreover, some MMPs were found to activate others
by cleaving their pro-domains (Sternlicht and Werb, 2001), resulting
in a hierocracy of events that regulate MMPs' activation and function.
Based on these activities, these proteases play a key role in EMT and
cell migration in angiogenesis, metastasis and tissue remodeling
(Coussens and Werb, 2002; McCawley and Matrisian, 2000; Reich et
al., 2005; Visse and Nagase, 2003).
The gelatinase subgroup of MMPs, composed solely of MMP2 and
MMP9, can hydrolyze denatured collagens (gelatins) with very high
efﬁciency, as well as native collagen types I, IV, ﬁbronectin and lami-
nin (Morrison et al., 2009; Rodriguez et al., 2010; Vu and Werb,
2000). MMP9 was previously found to be involved in mammalian
bone formation by promoting vascular invasion into the growth
plate (Vu et al., 1998). Although its molecular mode of action in tissue
invasion is not certain, it is speculated that MMP9may release growth
factors from the matrix (Engsig et al., 2000; Sternlicht and Werb,
2001) as well as contribute to degradation of the ECM. Notably, the
avian MMP9 possesses a number of biochemical and amino acid se-
quence features that differs it from its mammalian counterpart; it
has low sequence similarity to the mammalian enzyme (59% on the
protein level), lacks the type V collagen domain and can cleave ﬁbro-
nectin, which is not a substrate for mammalian MMP9 in in vitro as-
says (Hahn-Dantona et al., 2000). We have previously studied the
expression and role of avian MMP9 in the process of growth plate vas-
cularization during endochondral ossiﬁcation in the chicken, conﬁrm-
ing this protein to be indeed the avian homologue of the mammalian
MMP9 (Dan et al., 2009; Hasky-Negev et al., 2008; Leach and
Monsonego-Ornan, 2007; Simsa et al., 2007a; Tong et al., 2003).
As NCC undergo EMT and acquire motility, it is highly possible that
MMPs play roles in this unique cell population. To date, only very few
studies examined these proteases in NCC; MMP2 was demonstrated
to be transiently expressed in avian NCC, and its inhibition perturbed
some (but not all) phases of NCC migration (Duong and Erickson,
2004). MMP2 and the general MMP inhibitor TIMP2 were also sug-
gested to be involved at later stages, during migration of NCC toward
the heart and gut (Anderson, 2010; Cai et al., 2000; Cantemir et al.,
2004). Descriptive data further demonstrated MMP14 expression in
NCC of Xenopus laevis embryos, (Harrison et al., 2004; Tomlinson et
al., 2009), and MMP8 in mouse NCC (Giambernardi et al., 2001).
This study analyzed whether other, yet unidentiﬁed MMPs, are
implicated in NCC migration, and discovered that MMP9/gelatinaseB is expressed in avian NCC during their emigration and migration
at the trunk and cranial levels of the neural axis. Detailed gain-and-
loss-of-function experiments revealed that MMP9 is essential to exe-
cute NCC EMT and migration, and that this activity is mediated by
degradation of laminin and N-cadherin. Together, this study uncovers
a novel role for MMP9 in promoting delamination and migration of
early embryonic NCC cells.Materials and methods
Embryos
Fertile Lohman chick eggs were incubated at 38 °C. For in vivo pro-
cedures, eggs were windowed and embryos visualized by injecting
black ink below the blastodisc. Following manipulations, embryos
were incubated up to the required stages, ﬁxed in 4% paraformalde-
hyde (PFA), dehydrated in 100% methanol, and stored at −20 °C.MMP9 cloning, transfection and zymography assay
Chick MMP9 (cMMP9) expression construct was generated by
cloning a 1349 bp fragment from avian chondrocyte cDNA (Tong et
al., 2003) containing an ATG start codon, signal peptide, prodomain
sequence, active site, ﬁbronectin II repeat domain and zinc binding
sequence. Primers used were: forward- ATGCTCCTGGCCCCGCT and
reverse- GGCTCAGGGCCAGAGCC. PCR ampliﬁcation was performed
in 1 unit Isis™ DNA polymerase using the following program: 95 °C/
5 min and 30 cycles of 95 °C/35 s, 53 °C/45 s, 72 °C/45 s. Fragment
was inserted into pCDNA3 plasmid (Invitrogen, New Mexico, USA)
in EcoRV sites. Mouse MMP9 (mMMP9) expression construct was
generated by cloning a 2193 bp fragment from mMMP9 cDNA-
containing vector 6309245 (Thermo Fisher Scientiﬁc Co., USA), con-
taining an ATG start codon, signal peptide, prodomain sequence, ac-
tive site, ﬁbronectin II repeat domains, zinc binding sequence and
hemopexin domain. Primes used were: forward- GCGATATCCACCAT-
GAGTCCCTGGCAGC, and reverse-GAGAGCTCCAGCTAGCACCTTTCCCT
CG. PCR ampliﬁcation was performed in 1 unit IsisTM DNA polymerase
using the following program: 95 °C/5 min and 35 cycles of 95 °C/30 s,
65 °C/30 s, 72 °C/3 min. Fragment was inserted into pCAGGS-IRES-GFP
vector in EcoRV (forward) and SacI (reverse) sites.
Transfection of 10 μg cMMP9 cDNAwas performed in rat chondro-
sarcoma (RCS) cell line as previously described (Ben-Zvi et al., 2006).
Selection of stably-transfected cells was obtained by addition of 1 μg/
ml G418 (Monsonego-Ornan et al., 2000). For zymography assay, cells
or media samples were separated on a gelatin-impregnated gel under
non-reducing conditions to test MMP9 gelatinolytic activity (Dan et
al., 2009). Gels were washed in 2.5% Triton X-100, incubated at
37 °C/16 h in calcium assay buffer, and stained with 0.5% Coomassie
R-250 (Simsa et al., 2007b).RT-PCR from embryos and neural tube explants
Total RNA was puriﬁed from whole embryos of 10, 16 and 25 so-
mites, or from pools of isolated mesoderm or neural tubes, collected
from similar stages. RNA was also collected from isolated neural
tube explants, either before or after culturing them in ex-vivo condi-
tions, as well as from NCC that migrated away from the cultured neural
tubes. Reverse transcription (RT) was performed using the RT-for-PCR
Kit (Clontech, CA, USA). cDNAwas ampliﬁed by PCR in 25 μl reaction so-
lution containing 2 μl cDNA, 1 unit Taq-polymerase, 25 μMof each dNTP
and 2 μM primers. Primers used were: MMP9 forward- ACCGTGCC
GTGATAGATGAT and reverse- AGCCACCAAGAAGATGCTGT. PCR was
carried out using the following program: 95 °C/5 min followed by
35 cycles of 94 °C/40 s, 56 °C/45 s and 72 °C/45 s.
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Trunk region of embryos of 16–18 somites were sectioned at the
level of the anterior segmental plate plus the last 3 somite pairs.
The cranial region of 6–8 somite-old embryos was sectioned at the
hindbrain level. Neural primordia, consisting of neural tube with pre-
migratory NCC, were isolated from the adjacent tissues using 25%
pancreatin and explanted onto dishes pre-coated with 50 μg/ml ﬁbro-
nectin (Sela-Donenfeld and Kalcheim, 1999). Neural tube explants
were incubated with the following media: (i) conditioned media
from control RCS cells, (ii) conditioned media from MMP9-
producing RCS cells, (iii) control CHO-S-SFM II media (Gibco BRL,
MD, USA) containing 1% or 2.5% DMSO, (iv) CHO-S-SFM II media con-
taining 5 μM or 12.5 μMMMP9 inhibitor I (Calbiochem, CA, USA), dis-
solved in 1% or 2.5% DMSO, respectively, (v) control or 12.5 μMMMP9
inhibitor I-containing media (as above) supplemented with Hoechst
stain (40 μg/ml, Sigma MO, USA). In rescue experiments, explant
media, consisting of control or 12.5 μM MMP9 inhibitor I, were
added for overnight after which media were replaced with fresh con-
trol media. In some experiments, a layer of control or MMP9-
producing RCS cells was prepared, on top of which explants were
placed. Unless indicated otherwise, explants were grown for 16 h,
ﬁxed in 4% PFA or 100% methanol and preceded for immunostaining
or microscopy visualizations. In some other experiments, explants
were incubated in control CHO-S-SFM II+Hoechst for 5 h followed
by addition of 12.5 μM MMP9 inhibitor I in 2.5% DMSO or 2.5%
DMSO as control for overnight.
In ovo procedures
Cell grafting
Control or MMP9-secreting RCS cells were grown to conﬂuence,
pelleted and re-suspended in minimal volume of DMEM medium
(Sela-Donenfeld and Kalcheim, 1999). The vitelline membrane of em-
bryos of 14–18 somites was removed at the level corresponding to
the segmental plate and a slit was performed along the dorsal edge
of the neural tube. Injection of cells was performed on top of the neu-
ral tube using a pulled glass capillary. Embryos were developed for
further 16 h before ﬁxation.
Addition of MMP9
Conditioned media from control or MMP9 cells were injected into
the lumen of the cranial and cervical neural tubes in embryos of 8–9
somites. Injection was performed twice in 3 h intervals. Embryos
were ﬁxed 3 h after the second injection.
Inhibition of MMP9
MMP9 inhibitor I (125 μM in 25% DMSO, dissolved in DMEM
media), or control solution (25% DMSO in DMEM) were injected
twice at 4 h intervals into the lumen of the caudal neural tube of 16
somite-embryos or into the cranial neural tube of 6-to 8-somite-
embryos, using pulled glass capillary. Embryos were incubated for
16 h before ﬁxation. For CM-DiI injections, CM-DiI (C-7000, Molecular
Probes) was dissolved in 100% ethanol to a concentration of 1 mg/ml.
Prior to injection, it was further diluted to a ﬁnal concentration of
0.1 mg/ml in 125 μM MMP9 inhibitor I solution in 10% sucrose. Solu-
tion was injected at the caudal neural tube of 12-somite embryos.
Electroporation
FITC-conjugated MMP9 morpholino (MO) antisense oligonucleo-
tides, directed against exon2–intron2 junction, or control MO se-
quence (GeneTools, OR, USA), were diluted in PBS to a working
concentration of 2 mM. pCAGGS-IRES-GFP vector over expressing
MMP9 or empty IRES-GFP vector were diluted in 1.25 M NaCl,
50 mM Tris–Cl, pH 8.5 to a concentration of 5 μg/μl. MOs and plasmids
were injected into the neural tube of embryos at similar stages/axiallevels as described above using pulled glass capillary. Electrodes
were placed at the left and right sides of the embryo. Electroporation
was performed with a BTX 3000 electroporator using four 45 ms
pulses of 16 V with 300 ms pulse intervals (Itasaki et al., 1999;
Sela-Donenfeld et al., 2009; Weisinger et al., 2008). Embryos were
incubated for 16 h before ﬁxation. The MO sequences are: MMP9:
5′-GTACCCATCACCTGCTCTTGGCTG3′ and Control 5′-CCTCTTACCT-
CAGTTACAATTTATA-3′. For rescue experiments, MO-electroporated
embryos were let to develop for 6 h before injection of MMP9-
media into the neural tube. Lumen embryos were incubated for ad-
ditional 10 h before ﬁxation.
In situ hybridization (ISH) and immunohistochemistry/immunoﬂuorescence
(IHC, IFC)
In situ hybridization (ISH) on whole-mounted embryos or on
parafﬁn-sections was performed as described before (Sela-
Donenfeld and Kalcheim, 1999), using DIG or ﬂuorescein-labeled
probes against chick MMP9 (Tong et al., 2003), Foxd3 (Groysman et
al., 2008), Krox20 (Weisinger et al., 2008) and Cad6B (Sela-
Donenfeld and Kalcheim, 1999), detected by alkaline phosphatase
(AP)-coupled anti-DIG or anti-ﬂuorescein antibodies and NBT/BCIP
or Fast-red substrates (Roche, Basel, Switzerland). Immunostaining
on whole-mounted embryos, neural tube explants, as well as on par-
afﬁn or frozen sections was performed by blocking the samples with
3% BSA/PBS and incubation with the following antibodies; mouse-
anti HNK1 (1:500, BD Pharmingen, CA, USA), mouse anti N-cadherin
(extracellular domain) (1:400, Sigma MO, USA), rabbit-anti laminin
(1:100, Sigma MO, USA), rabbit-anti phospohystone 3 (1:50, Santa
Cruz Biotechnology, CA, USA), or rabbit anti-MMP9 (1:100, Abcam,
CA, USA) at 4 °C/16 h. Antigen retrieval was performed prior to addi-
tion of laminin and N-cadherin antibodies to sections by boiling the
sections for 5 min in 100 mM Tris pH 9.5. Secondary anti-mouse
Alexa 488, anti-rabbit Alexa 488, anti-rabbit Alexa 594 and anti-
mouse Alexa 594 (all 1:500, Molecular Probes, CA, USA), or anti-
mouse HRP (1:300, Sigma MO, USA) antibodies were added at RT
for 2 h after which embryos were visualized under ﬂuorescence mi-
croscopy or stained with ACE substrate system (LabVision, CA, USA)
to reveal HRP activity. To detect FITC-conjugated-MO oligonucleo-
tides, AP-coupled anti-ﬂuorescein antibody (1:2000, Roche, Basel,
Switzerland) was added for 16 h at 4 °C, followed by addition of
NBT/BCIP substrate. Actin ﬁlaments were stained by incubating ex-
plants with Phalloidin (1:500 Sigma MO, USA) for 1 h at RT followed
by washes with PBS/Tween. Cell nuclei were visualized with 4′,6′-dia-
midino-2-phenylindole (DAPI) (1:7500, Vector Laboratories, CA,
USA) for 20 min at RT.
Data analysis and imaging
Quantiﬁcation of migratory NCC in explants was calculated as a
mean of 5–10 explants per treatment, out of 20–25 embryos showing
a similar phenotype. The area occupied by migrating NCC was calcu-
lated by ImageJ software for area-measurements using the following
formula: total area occupied by both ‘epithelioid’ NCC plus all mesen-
chymal NCC, divided by the total area of the neural tube. Area of mes-
enchymal cells was determined by calculating the average area of 10
separated HNK1+ cells and thereafter multiplying it by the number of
mesenchymal cells. In timed-inhibition experiments, the migration
areas of NCC after overnight experiment were calculated as described
above, with subtraction of the migratory NCC areas after the ﬁrst 5 h.
In all experiments bars represent mean areas of the results in arbi-
trary units and standard deviation is provided. Signiﬁcance of results
was determined using the unpaired Student's t-test. Quantiﬁcation of
migratory NCC in CM-DiI experiments was performed by counting
DiI+HNK1 positive cells in both sides of the neural tube in 5
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mean of number of cells.
Summary of total embryos and percentages for each experiment
and treatment are provided in Table 1.
Whole embryos were analyzed under SZX17 stereomicroscope
(Olympus). Explants and sections were analyzed using Eclipse E400
upright microscope (Nikon) or SZX17 stereomicroscope (Olympus).
All Images were taken with DP70 CCD camera (Olympus) and DP con-
troller software.
Results
MMP9 is expressed in pre-migrating and migrating NCC
The gelatinase subfamily of MMPs is composed of two members,
MMP9 and MMP2 (Hahn-Dantona et al., 2000; Malemud, 2006a). As
MMP2 was previously suggested to be involved in NCC migration
(Cai et al., 2000; Cantemir et al., 2004; Duong and Erickson, 2004),
we were set to determine whether the other gelatinase, MMP9,
plays a role in NCC migration. We ﬁrst examined its expression in
various embryonic stages and axial levels where NCCmigration occurs,
using RT-PCR (Fig. 1A). RNA was extracted from pools of whole embry-
os of 10, 15, 25 somites, stages when NCC migrate from cranial, vagal
and trunk levels of the neural axis respectively, and from isolated neural
tubes or paraxial mesoderm to examinewhether MMP9 is expressed at
areas associated with NCC delamination and migration. MMP9 was
found in all examined stages as well as in the puriﬁed mesoderm and
neural tubes. In addition, MMP9 mRNA was expressed in ex-vivo ex-
plants obtained from hindbrain levels of 5–8 somite-stage embryos, be-
fore or after culturing the neural tube, as well as in NCC that detached
from the explants and migrated in the dish (Fig. 1A′). Together, these
results indicated the presence of MMP9 transcripts in NCC as well as
in regions where cells migrate into.
To further characterize the spatial distribution of MMP9, ISH was
performed on whole-mounted embryos and on transverse sections,
using MMP9-speciﬁc antisense probe (Figs. 1B,C,E,G,H,I). MMP9 ex-
pression was compared with expression of other genes such as
Cad6B and Foxd3 (Figs. 1D,F,G) which mark premigratory and migrat-
ing NCC (Dottori et al., 2001; Nakagawa and Takeichi, 1995) as well as
with Krox20 (Fig. 1C), which served to label the odd-numbered rhom-
bomeres of the hindbrain (Nieto et al., 1991). MMP9 is expressed in
the dorsal part of the cranial neural tube in embryos of 15 somites,
as well as in the migratory routes of NCC into the mid-and hindbrain
mesoderms (Figs. 1B,C,H). Co-labeling of MMP9 and Krox20 (Fig. 1C)Table 1
Summary of embryos examined for NCC migration following in vivo addition or inhibi-
tion of MMP9.
Treatment Normal NCC
migration
Reduced
NCC
migration
Enhanced
NCC
migration
Total percentage of
altered migration
DMSO 39 4 0 9% n=43
MMP9 inhibitor I 12.5 μM 9 39 0 81% n=48
Control-MO 30 5 0 14% n=35
MMP9-MO 8 29 0 78% n=37
MMP9-MO Rescue 2 0 5 71% n=7
Control RCS cells 12 0 0 0% n=12
MMP9-secreting RCS cells 1 0 11 92% n=12
Control media 9 1 0 10% n=10
MMP9 media 3 0 8 73% n=11
Control- empty pCAGGS 8 0 0 0% n=8
pCAGGS mMMP9 0 0 7 100% n=7
Data shows the number of embryos that exhibit normal, reduced or enhanced NCC
migration, evaluated by HNK1 staining, and the total percentage of altered migration
upon different treatments. n = total number of embryos per treatment.further demonstrates the localized MMP9 expression in the typical
streams of NCC adjacent to the even-numbered segments, which are
Krox20-negative (Farlie et al., 1999; Graham and Lumsden, 1996).
Further conﬁrmation for the speciﬁcMMP9-expression in the migrat-
ing hindbrain NCC is evident by its similar distribution to that of
FoxD3 (Fig. 1D). At the trunk level of embryos of 25 somites, MMP9
is shown in the dorsal neural tube, in NCC during theirmigration toward
the paraxial mesoderm and at the anterior half of somites (Figs. 1E,G,I).
The co-localization of MMP9 and Cad6B at the dorsal tube (E–G) further
conﬁrms the speciﬁc MMP9-expression in pre-migratory trunk NCC.
This analysis, together with our RT-PCR results, indicates that MMP9
mRNA is distributed in the cranial and trunk NCC during their detach-
ment from the neural tube and their migration.
To conﬁrm the presence of MMP9 protein in NCC, we next exam-
ined embryos using MMP9 antibody. Sections were taken from hind-
brain (Figs. 1J–L) and trunk axial levels (Figs. 1M–O) of 15 or 25
somite-old embryos, respectively. At both stages, MMP9 was clearly
evident in the emigrating and migrating NCC (Figs. 1J,L,L′,M,O,O′),
as shown by co-staining with the migratory NCC marker HNK1
(Figs. 1K–L′,N–O′), validating further the identity of the MMP9-
expressing cells as NCC. Notably, early-migrating NCC that were still
adjacent to the neural tube seemed to express MMP9 but not HNK1
(Figs. 1L,O). This is in agreement with previous reports in which
HNK1 staining in evident in NCC that are more advanced in migration
(Erickson, 1988; Sela-Donenfeld and Kalcheim, 1999). The secreted
MMP9 is mostly bound to NCC membrane or trapped in the ECM/
basement membrane around the cells. MMP9 is also evident in ecto-
derm cells and in the basement membrane around the neural tube,
notochord and myotome (Figs. 1J,M), as also observed by the ISH
analysis (Figs. 1H,I). These regions, which are along the migratory
routes of NCC, suggest that MMP9 is produced in more cells than
only in NCC, implicating that, in addition to NCC themselves, their
surrounding environment also produces MMP9.
Next, MMP9 distribution was examined in NCC growing in ex-vivo
conditions. Explants of neural primordia that contain pre-migratory
NCC were dissected from hindbrain levels of embryos of 5–8 somites,
freed from accompanying tissues, and cultured in ﬁbronectin-coated
dishes. After 16 h of incubation migratory NCC were evident around
the neural tube explants (Fig. 1P). Staining with MMP9 antibody
revealed many migrating NCC that express MMP9 protein in the cyto-
plasm (Figs. 1Q,S,T). Comparison with HNK1 staining revealed more
cells expressing MMP9 than HNK1 (Figs. 1R,S), probably since
MMP9 expression is evident in NCC prior to HNK1, as also seen in-
vivo (Figs. 1L,O, see alsoNewgreen andMinichiello, 1995) Alternatively,
it is possible that not all NCC are HNK1-positive in the ex-vivo condi-
tions. Some MMP9 staining was also evident in-between cells (Fig.
1T), reﬂecting secreted MMP9 from the NCC to the ECM. Altogether,
these analyses demonstrate the expression ofMMP9mRNA and protein
in the emigrating and migrating NCC, as well as in regions along their
migration pathways.
Inhibition of MMP9 prevents NCC delamination and migration
To determine whether MMP9 plays a role during NCC detachment
from the neural tube, we examined the effect of blockingMMP9 activity
on NCC emigration in ex-vivo explants, using a pharmacological inhibi-
tor (Fig. 2). Explants of neural primordia were dissected from either the
segmental plate plus 3 posterior somites of embryos of 16–18 somites
(Figs. 2A–F), or from hindbrain levels of embryos of 6–8 somites
(Figs. 2G–L). These regions contain predominantly speciﬁed NCC,
prior to their onset of migration (Sela-Donenfeld and Kalcheim, 1999).
A speciﬁc MMP9 inhibitor, MMP9 inhibitor I (Levin et al., 2001) was
added to the explants media in two different concentrations — 5 μM
or 12.5 μM. Control explants were treated with DMSO in equivalent
amounts to those used to dissolve the inhibitor (1% or 2.5% DMSO, re-
spectively). In general, after 16 h of incubation, NCC largely failed to
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Fig. 1. MMP9 is expressed in NCC. (A): RT-PCR analysis on mRNAs puriﬁed from whole embryos of 10, 15, 25 somites or from pools of isolated neural tubes/paraxial mesoderm
obtained from similar stages. (A′): RT-PCR analysis on mRNAs puriﬁed from neural-tube explants obtained from hindbrain levels of 5–8 somite-old embryos, either before or
after culturing them in ex-vivo conditions, as well as from NCC that migrated away from the explants. Primer pairs used in (A,A′) were directed against a 120 bp long sequence
of chick MMP9. (B–G): In situ hybridization on whole-mounted embryos of 15/25 somites labeled with RNA probe against MMP9 (B,C,E,G), Krox20 (C), FoxD3 (D) and Cad6B
(F,G). Embryo in (C) was double-labeled with MMP9 (blue) and Krox20 (purple) probes. Image in (G) is a digital merge of two identical embryos (E,F) stained with MMP9 (E)
and Cad6B (F). (H,I): serial sections taken from the dotted areas in B,E. Black arrowheads in (B–I) indicate NCC which express MMP9 (B,C,E,G,H,I), FoxD3 (D), or Cad6B (F,G).
(J–O): Immunolabeling of transverse sections obtained from embryos of 15/25 somites using MMP9 (green,J,L,M,O) or HNK1 (red, K,L,N,O) antibodies. Blue staining in (L,O) rep-
resents DAPI staining. White arrowheads indicate MMP9 or HNK1 positive cells. Panels L′,O′ are enlargement of the boxed areas in panels L,O. (P–T): immunolabeling of neural tube
explants using MMP9 (green) and HNK1 antibodies (red). Bright ﬁeld view is shown in P. Dashed circle in P represents borders of NCC-migratory areas. Panel T is an enlargement of
the boxed area in panel S. White arrowheads indicate MMP9/HNK1 positive NCC. Pink arrowhead represents MMP9-positive/HNK-negative NCC. Green arrowhead indicates MMP9
protein around cells. In all images, stages, treatments and staining are indicated. NT; neural tube; mes-mesoderm; ss, somite-stage; neg, negative control; NT exp, neural tube ex-
plant; NCC, migratory NCC; r, rhombomere.
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(Figs. 2B,D,H,J); while less NCC emigrated in the presence of 5 μM
MMP9 inhibitor, as compared to controls (compare Fig. 2A with B,
n=8, 10 respectively and Fig. 2G with H, n=15, 12 respectively), a
more dramatic inhibition was found in the presence of 12.5 μM inhibi-
tor (compare Fig. 2C with D, n=25, 20 respectively and Figs. 2I with J,
n=22, 25 respectively). Furthermore, HNK1 staining of explants
shown in Figs. 2C,D,I,J revealed extensive migration of HNK1+–NCC in
controls (Figs. 2E,K,), compared to explants treated with MMP9 inhibi-
tor I (Figs. 2F,L). Quantiﬁcation of the inhibitory effects revealed a 4.7
fold decrease in the area of migrating NCC in the presence of MMP9 in-
hibitor as opposed to control value (Fig. 2U, n=7 cultures out of 20 ex-
plants, respectively).
We next analyzed whether the effect of the MMP9-inhibitor on
NCC is transient. Another set of cranial-derived explants were treated
with 12.5 μM MMP9-inhibitor for overnight (12 h) and revealed pre-
vention of NCC emigration in the treated explants (Fig. 2N, n=5),
compared to controls (Fig. 2M, n=6), similar to the results shown
above (Figs. 2G–J). However, additional incubation of these explants
for 16 more hours revealed that migratory NCC began to appear
around the explants that were treated with MMP9 inhibitor 28 h
ago (Fig. 2P), although to a lesser extent as compared to the control
explants (Fig. 2O). This result suggests that the activity of the inhibi-
tor is reduced with time, and that the treated explants remain viable
in the presence of the chemical inhibitor as evident by the retained
migratory behavior.
A rescue experiment was also performed on cranial neural tube
explants (Figs. 2Q–T). Following application of MMP9-inhibitor I for
overnight, the inhibitory media were replaced with a control media
and the explants were followed with time. Similarly to our previous
results (Figs. 2G–N), NCC were prevented from detaching from theneural primordia upon addition of MMP9 inhibitor (Fig. 2R, n=5),
in contrast to control explants (Fig. 2Q, n=5). However, the removal
of the inhibitory media resulted in restoration of NCC capacity to de-
laminate and migrate (Figs. 2S,T). This rescue was enhanced with
time, as many more cells were observed around the explants after
16 h (Fig. 2T) compared to 6 h (Fig. 2S), following the removal of
the inhibitor. This assay further indicates the reversibility of the in-
hibitory effect of MMP9-inhibitor I and shows that prevention of
NCC emigration is not due to a cytotoxic effect on the explants or
loss of NCC progenitors. Taken together, the data shown in Fig. 2
demonstrates that inhibition of MMP9 prevents cranial and trunk–
NCC from delaminating from the neural tube in ex-vivo conditions.
The distribution of MMP9 is evident in both emigrating and mi-
grating NCC (Fig. 1). We thus aimed to determine whether the effect
of MMP9-inhibiton is restricted only to the delamination process (as
examined in Fig. 2), or whether it also affects the migration of NCC.
An additional set of cranial neural tubes was explanted in ex-vivo
conditions (as described in Fig. 2) and was followed as a function of
time (Fig. 3). Notably, part of the explants grew in media added
with the nuclear dye Hoechst to stain the living cells (Figs. 3A–D),
whereas others grew in normal condition media (Figs. 3E–H). First,
all explants were let to develop for 5 h without any treatment. Initial
delamination and migration of cells were clearly visible around the
neural tube explants, as evident in the bright-ﬁeld views (Figs. 3E,F
n=8) and in the Hoechst-labeled explants (Figs. 3A-B' n=10). Sub-
sequently, explants were added with MMP9-inhibitor for additional
15 h and compared to controls. While control explants demonstrated
a signiﬁcant increase in the number of NCC around the explants and
in the distance of their migration in the dish (Figs. 3C,C', G n=8),
the early-migrating NCC did not migrate much further in the MMP9
inhibited explants (Figs. 3D,D',H n=10). In addition, there was
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Fig. 2. Blocking MMP9 activity inhibits NCC delamination in cultured neural tubes. A–D, G–J, M–T: Bright-ﬁeld images of neural tubes derived from segmental plate plus last 3 so-
mites of embryos of 16–18 somites (A–D), or from hindbrain levels of embryos of 6–8 somites (G–J, M–T). Explants were grown for 16 h in medium containing 1% (A,G) or 2.5% (C,I,
M,O) DMSO, 5 μM MMP9 inhibitor I in 1%DMSO (B,H), 12.5 μM MMP9 inhibitor I in 2.5% DMSO (D,J,N,R). (E,F,K,L): HNK1 antibody staining of explants shown in (C,D,I,J). (M–P):
Control (M,O) and MMP-9 inhibited explants (N,P), treated as in (I,J) and showed after 12 and 28 h of incubation. (Q–T): Rescue of the MMP9-inhibitory effect. Explants in (Q,R)
were cultured as in (I,J). (S,T): Replacement of the inhibitory media in the explant shown in (R) with control media, and evaluation of NCC migration 6 and 16 h later. (U): Quan-
tiﬁcation of the ratio between migration areas of cranial NCC to explants area, upon addition of 12.5 μM MMP-9 inhibitor versus control explants. Bars represent mean with stan-
dard deviation. Treatments, concentrations used and times of evaluations are indicated. Dashed lines represent borders of NCC-migratory areas. NT; neural tube.
167E. Monsonego-Ornan et al. / Developmental Biology 364 (2012) 162–177much less increase in the number of cells around the neural tubes
after the overnight treatment. Staining of some of these explants
with HNK1 further demonstrated the sharp differences in the migra-
tion area of control versus MMP9-inhibited explants (Figs. 3I,J).
Quantiﬁcation of the inhibitory effect of MMP9-inhibitior on the mi-
gration of the cells showed 3 fold decrease in the area occupied by
NCC in inhibited explants compared to control explants (Fig. 3K). Al-
together, the data shown in Figs. 2,3 allows us to distinguish between
the effect of MMP9 inhibition on delamination versus migration, and
demonstrates that MMP9 inhibition prevents both the initial delami-
nation of NCC as well as their migration. The suggested role of MMP9
in delamination andmigration of NCC is in agreement with MMP9 ex-
pression patterns which are evident in the emigrating and migrating
cells (Fig. 1).
To continue testing the possibility that MMP9 is required for
NCC emigration, we turned to in-vivo experiments, in which thepharmacological inhibitor was injected into the neural tube. Solution
containingMMP9 inhibitor I (125 μM) or DMSOwas injected together
with the membrane tracer CM-DiI, into the caudal neural tube of 12
somite embryos. At this stage, caudal NCC are still conﬁned to the
neural tube while more anterior cells are already undergoing migra-
tion. The addition of the DiI enabled to examine the distribution of
the inhibitor along the neural tube and in the migrating NCC, which
are DiI-labeled upon detachment from the neural tube. Embryos
were injected twice in 4 h intervals and left to develop for 16 h. The
caudally-injected MMP inhibitor I/DiI-solution extended rostrally
(Fig. 4A), conﬁrming that the inhibitor reaches trunk and cranial pre-
migratory NCC in our experimental system. Migration of NCC was
assessed by examining DiI and HNK1 staining in transverse sections
obtained from an anterior (somite 5) and posterior (somite 20)
axial levels (Figs. 4B–E, Table 1). In control sections obtained from an-
terior axial levels, migratory HNK1+/DiI+ NCC were clearly evident
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Fig. 3. Blocking MMP9 activity inhibits NCC migration in explants. Explants from hindbrain levels of embryos of 6–8 somites were grown for 5 ﬁrst hours in control media (E,F) or in
control media supplemented with Hoechst stain (A,B). In the following 15 h, explants were added with media containing 2.5% DMSO as control (C,G) or 12.5 μMMMP9-inhibitor I in
2.5% DMSO (D,H). (A–D): Fluorescent images of Hoechst-stained explants. Panels A′,B′,C′,D′ are enlargement of the boxed areas in panels A,B,C,D. (E–H): Bright-ﬁeld images of ex-
plants. (I,J): HNK1 staining of explants in (G,H) respectively. (K): Quantiﬁcation of the results obtained by measuring the ratio between migration areas of NCC to explants area and
subtracting the ﬁrst 5 h from overnight results. Bars represent mean with standard deviation. Treatments and times of evaluations are indicated. Dashed lines represent borders of
NCC-migratory areas. NT; neural tube.
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most no DiI labeling of migrating NCC was evident (Fig. 4C, C',
n=5), as well as a dramatic reduction in the migrating HNK1+–
NCC was found. The remaining HNK1 labeling at these rostral levels
is likely to represent NCC that were already migrating when MMP9
inhibition was applied, and are thus not labeledwith DiI. Similar results
were found at the caudal level of the neuroaxis (Figs. 4D,E), although at
this embryonic region less NCC are normally engaged in migration. Yet,
while DiI+/HNK+ cells were evident around the neural tube in controls
(Fig. 4D, D' n=5), almost no migrating NCC were evident in the
MMP9-inhibited embryos (Fig. 4E, E' n=5). Noticeably, the red dots
shown in Fig. 4E do not represent NCC, but ectodermal and neural tube
stainings. Quantiﬁcation of DiI+/HNK+ cells in control versus MMP9
inhibited embryos revealed 3.5 fold decrease in inhibited embryos.
NCC migration is a highly dynamic process which extends from as
early as ~5 somites up to much later stages at different rostro-caudal
levels. A previous study performed on the other gelatinase MMP2,
showed that inhibition of MMP2 prevented trunk NCC from undergo-
ing EMT at staged 12 HH (16 somites), but not at later stages (26 so-
mites) (Duong and Erickson, 2004). Therefore, we assessed whether
the effect of the MMP9 inhibition is restricted only to some stages
of NCC migration, or alternatively, whether it affects NCC migration
at multiple stages. The inhibitor was injected into either the cranial
neuroepithelium of embryos of 5–8 somites (Figs. 4G,H) or into the
caudal neural tube of 18 somite-embryos (Figs. 4I,J). In embryos
injected with control solution at cranial levels, NCC migrated exten-
sively into the head and cervix mesenchyme (Fig. 4G, n=16). Incontrast, embryos injected with MMP9 inhibitor revealed signiﬁcant-
ly weaker HNK1 staining (Fig. 4H, n=16), especially at the posterior
regions of the cranial neural tube. Serial sections taken from these
embryos conﬁrmed that many HNK1 labeled cells are seen in con-
trols, lateral to the neural tube and during their ventral migration at
midbrain and hindbrain levels (Figs. 4K,M). Conversely, a dramatic
decrease in NCC migration is evident at the midbrain and hindbrain
levels of embryos injected with MMP9 inhibitor I (Figs. 4L,N). Con-
comitantly with these results, injection of the inhibitor into caudal
neural tubes resulted in a dramatic reduction of migratory NCC,
seen both in whole-mounted embryos (Fig. 4J, n=16) and in sections
(Fig. 4P). In contrast, control embryos revealed typical HNK1 positive
cells lateral to the neural tube, and during their migration ventrally
and into rostral portions of somites (Figs. 4I,O n=16). Altogether,
these data indicate that inhibition of MMP9 prevents NCC from emi-
grating from the neural tube at multiple axial levels and stages.
We next used the Foxd3marker to further assess the effect of MMP9
inhibition on premigratory as well as on migrating NCC (Figs. 4Q–T)
(Dottori et al., 2001). Normal Foxd3 expression was evident in control
embryos both in NCC progenitors that are conﬁned to the dorsal neuroe-
pithelium and in migrating cells (Figs. 4Q,S n=5). In contrast, MMP9-
inhibitor treated embryos showed an increase in Foxd3 expression in
the dorsal portion of the neural tube while no Foxd3 expressing cells
were found migrating (Figs. 4R,T n=8). These results indicate that inhi-
bition of MMP9 does not prevent NCC speciﬁcation but inhibits their mi-
gration away from the neuroepithelia and conﬁrms further our data that
MMP9 inhibition prevents NCC migration in vivo and ex vivo.
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Fig. 4. Blocking of MMP9 activity inhibits NCC migration in ovo. (A): Whole-mount view of embryo injected with CM-DiI/MMP9-inhibitor I (125 μM) solution into the neural tube at
the entire length of the neuroaxis of 12 somite-old embryos. (B–E): Serial sections taken from anterior (B–C) and posterior (D–E) levels of embryos injected with control (B,D) or
MMP9 inhibitor I (C,E) solutions. Panels B′,C′,D′,E′ are enlargement of the boxed areas in panels B,C,D,E. Red represents DiI, green represents HNK1, blue represents DAPI staining.
White arrows mark DiI and HNK1 positive cells. (F): Counts of DiI and HNK1 positive cells in control versus MMP9 inhibited embryos. Bars represent mean with standard deviation.
(G–J) Whole-mount views of HNK1 stained embryos injected with control (G,I) or MMP9 inhibitor I (H,J) solutions into the neural tube at the cranial levels of 6–8 somites embryos,
(G,H), or at caudal regions of embryos of 16 somites (I,J). (K–P): Serial sections taken from the dotted areas in (G–J), respectively. (Q,R): Whole-mounted embryos, treated similarly
to embryos shown in (I,J,) and hybridized with Foxd3 probe. (S,T): Serial sections taken from dotted lines in Q,R, respectively. In all images, black arrows mark HNK1 and Foxd3
positive NCC. Treatments are indicated.
169E. Monsonego-Ornan et al. / Developmental Biology 364 (2012) 162–177The role of MMP9 in the migration onset of NCC was next exam-
ined by an additional loss-of function approach (Fig. 5 and Table 1).
FITC-conjugated morpholino-antisense oligonucleotides (MO), di-
rected against the second exon–intron splice junction of chick
MMP9 was utilized in order to produce a misspliced MMP9 mRNA
(Eisen and Smith, 2008). First, the activity of the MO to knock-down
the production of MMP9 was assessed by electroporating MMP9-
MO or control-MO (FITC, green) into the cranial neural tube of ~6
somite-old embryos, and staining with anti-MMP9 antibody (red)
18 h later (Figs. 5A,B). In control embryos MMP9 expression was evi-
dent adjacent to the neural tube and the basement membrane around
the neural tube (Figs. 5A,A′). In contrast, embryos electroporated with
MMP9-MO demonstrated a marked decrease in MMP9 protein expres-
sion (Figs. 5B,B′), conﬁrming the potency of the MMP9-MO to decrease
MMP9 production. The migration of NCC was then assessed by electro-
porating both MO's into the mid- and hindbrain regions of ~5 somite-
old embryos (Figs. 5G,H) or into the caudal neural tube of 18 somite-old
embryos (Figs. 5C,D). Immunostaining against HNK1 (orange) and
FITC-MO (blue) was performed 18 h later. Control embryos demon-
strated typical HNK1-positive NCC that migrate at the head and trunk
axial levels (Figs. 5C,G, n=12 for each), at both the electroporated
and the contra-lateral sides of the neural tube. A signiﬁcant reduction
of HNK1-stained cells was evident in embryos expressing MMP9-MO,both at the cranial and trunk levels of the neuroaxis (Figs. 5D,H n=12
for each). These results were also conﬁrmed by HNK1-labeling of trans-
verse sections taken from control (Figs. 5E,I) andMMP9-MO (Figs. 5F,J)
embryos. Notably, the effect of MMP9-MO was observed on both sides
of the neural tube. This may be a result ofMO-electroporation occurring
atmuch lower levels also at the contra-lateral neural tube that is harder
to detect in our system (Figs. 5E,F,I,G), see also Weisinger et al. (2008).
Alternatively, as MMP9 is a secreted protein that acts at the ECM in a
limiting concentration, it is highly possible that its knockdown causes
it to be less available also in areas outside of the knockdown cells.
These results are further conﬁrmed in the embryos stained with
MMP9 antibody (Figs. 5A,B), in which reduction of MMP9 expression
is also visible in larger areas than theMMP9-MOelectroporated regions.
To further conﬁrm the requirement of MMP9 for migration of NCC, we
performed a rescue experiment (Figs. 5K–P), by electroporation of
MMP9-MO followed by injection of MMP9-enriched media into the
neural tube (see Figs. 6,7 for details about MMP9-conditioned media
and their effect onNCCmigration). Our results show retention ofmigra-
tory NCC in the rescue experiment, as revealed by HNK1 staining (Figs.
5M,P, n=6), as compared to the MMP9-MO (Figs. 5L,O n=7) and con-
trol (Figs. 4K,N, n=7) embryos. This result supports our previous ﬁnd-
ings and rules out the possibility of a toxic effect of the MO treatment.
Moreover, the increase in HNK1-positive cells in rescued embryos
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Fig. 5. Electroporation of MMP9-MO prevents NCC migration. (A–B): Transverse sections taken from embryos electroporated at the stage of 6 somites with FITC-conjugated control-
MO (A) or MMP9-MO (B) and labeled with MMP9 antibody. Red and green staining shows MMP9 and MO-expressing cells, respectively, blue represents DAPI stain. Images in A′,B′
are enlargements of the boxed areas in A,B. (C,D,G,H,K–M): Whole-mount images of HNK1 stained embryos, electroporated at the stage of 18 somites (C,D) or 5 somites (G,H,K–M)
with FITC-conjugated control-MO (C,G,K) or MMP9-MO (D,H,L,M). Embryo in (M) was injected with MMP9-enriched media 6 h after the electroporation. (E,F,I,J,N–P): Serial sec-
tions taken from the dotted lines in (C,D,G,H,K–M), respectively. Brown and blue stains show HNK1 and MO-expressing cells, respectively. In all images, treatments are indicated.
Black arrows mark HNK1 positive NCC, white arrows mark MMP9 staining.
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gain-of-function experiments (see Figs. 6–7). To additionally eliminate
the possibility of a non-speciﬁc effect of the MMP9-MO, we tested
whether it affects cell proliferation and cell death in the neural tubes.
Electroporation of both control-MO and MMP9-MO did not affect the
mitotic divisions of cells at each side of the neural tube, as shown by
anti-pH3 staining (Supplementary Fig. 1), nor did it reveal any exces-
sive cell death, as shown by TUNEL assay (Supplementary Fig. 1). To-
gether, these results support our previous experiments (Figs. 2–4) and
conﬁrm that MMP9 is required for NCC delamination and migration at
multiple axial levels and embryonic stages.
Addition of exogenous MMP9 induces enhanced migration of NCC
We next studied whether exogenous MMP9 will enhance NCC mi-
gration from the neural primordia. To generate a tool to increase
MMP9 activity, we established a cell line of rat chondrosarcoma
(RCS) constantly expressing MMP9. Chick MMP9 cDNA, including
the signal peptide, binding and catalytic sites of MMP9 and excluding
the c-terminal hemopexin regulatory domain, was cloned into
pCDNA3 construct and transfected into RCS cells that were selectedfor MMP9 stable production (Ben-Zvi et al., 2006; Weizmann et al.,
2005). The gelatinolytic activity of the MMP9 was demonstrated in
cell lysates and cultured media, using gelatin impregnated zymogra-
phy gel (Figs. 6A,B). This assay conﬁrms that the cells express the
transfected 40 kDa MMP9 which is secreted into the media as an ac-
tive enzyme. The increasing levels of active MMP9 were found in
the media, but not in cells, as expected for secreted MMP (Figs. 6A,
B). An additional 62 kDa band is also observed in both control and
MMP9-transfected cells, corresponding to the endogenous MMP2,
which is expressed at low levels in RCS cells (Tong et al., 2003).
Conditioned media from control or MMP9-transfected cells were
added to neural tube explants, isolated either from posterior segmental
plate or from hindbrain levels of 16 or 6 somite-old embryos, respec-
tively (Figs. 6C–J, Table 1). As expected following 16 h of incubation,
NCC delaminated and migrated in control explants of both head and
trunk regions, as shown in bright-ﬁeld images as well as following
HNK1 staining (Figs. 6C,E,G n=15 for each region, respectively). Addi-
tion of MMP9-media signiﬁcantly enhanced the outgrowth of NCC
from cranial and trunk neural tubes (Figs. 6D,F,H n=16 for each re-
gion, respectively). Quantiﬁcation of these results revealed 1.4 fold in-
crease in the area of migrating NCC in the presence of excess MMP9 as
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Fig. 6. Enhanced EMT and migration of NCC in explants treated with excess MMP9. (A,B): A rat chondrosarcoma cell line (RCS) was transfected with an empty pCDNA3 vector (EV)
or with a vector containing avian 40 kDa MMP9 insert (MMP9). At the indicated times, samples of cells (A) or conditioned media (B) were collected and analyzed under non-
reducing conditions on gelatin zymography. Bands corresponding to the endogenous 62 kDa MMP2 and the transfected 40 kDa MMP9 are detected. (C–F): Bright ﬁeld images of
isolated neural tubes from segmental plate levels of 16 somite-old embryos (C,D) or hindbrain levels of 6 somite-old embryos (E–F) that were seeded onto ﬁbronectin-coated dishes
and grown 16 h in control RCS media (C,E), or in MMP9-containing RCS media (D,F). Dashed circles represent borders of NCC migration area. (G–J): HNK1 antibody staining of ex-
plants derived from hindbrain levels of 6 somite-old embryos that were either grown on ﬁbronectin coated dishes with control (G) and MMP9-media (H) or seeded on top of con-
trol RCS (I) and MMP9 RCS (J) cell layers. (K): Quantiﬁcation of migrating cranial NCC area upon addition of MMP-9 media versus control explants. Bars represent mean and
standard deviation. (L–M″): Explants treated with control (L) or MMP9-enriched media (M) and stained with phalloidin. Images in L′,L″,M′,M″ are enlargements of areas marked
in L,M by white arrowheads. (N–O″): Explants treated with control (N) or MMP9-media (O) that were examined for N-cadherin distribution at cell membranes. Images in N′,N″,O′,O″
are enlargements of boxed areas in N,O. Green represents N-cadherin and blue represents DAPI stain. In all images treatments are indicated. NT; neural tube.
171E. Monsonego-Ornan et al. / Developmental Biology 364 (2012) 162–177compared to control values (Fig. 6K, n=10 cultures out of 15 explants
for each treatment). In a parallel approach neural primordia isolated
from cranial levels were explanted on top of control or MMP9-
producing RCS cell layers. The explants were labeled with HNK1 16 h
later (Figs. 6I,J). In general, the migration of NCC on top of RCS cells
was less efﬁcient, as compared to ﬁbronectin-coated dishes. Yet, a
large amount of cells expressing HNK1were found around the explants
seeded on top of MMP9-secreting cells (Fig. 6J, n=5), while much
fewer HNK1+-cells grew on control RCS (Fig. 6I, n=5). Notably, in
both types of experiments, excess MMP9 did not affect the integrity
of the neural tubes (Figs. 6C–J), indicating that MMP9 acts speciﬁcally
to enhance NCC migration rather than to induce general protein degra-
dation and dissociation of cells in culture.
The effects of MMP9 were also examined on the epithelial/
mesenchymal characteristics and shape of the excessively migratingNCC. Stainingwith phalloidin, that binds to the actin ﬁlaments of the cy-
toskeleton (Groysman et al., 2008;Wright et al., 1988), reveled the typ-
ical organization of stretched stress-ﬁbers in migratory NCC around the
control explant (Figs. 6L–L″ n=18). However, the organized structure
of stress-ﬁbers was perturbed in NCC migrating in MMP9-treated ex-
plants (Figs. 6M–M″ n=14), suggesting accelerated loss of epithelial
morphology upon excess MMP9 and transition toward mesenchymali-
zation. Epithelial properties of the cells were also examined by staining
for N-cadherin, an adhesion molecule known to accumulate at the api-
cal membrane of neuroepithelial cells and to be downregulated in mes-
enchymal cells (Groysman et al., 2008; Nakagawa and Takeichi, 1998;
Shoval et al., 2007; Taneyhill, 2008). Staining of control explants
revealed a typical N-cadherin localization in NCC membranes that mi-
grated around the neural tube (Figs. 6N–N″, n=12), and its absence
in cells that moved further away from the explant (Fig. 6N″). In
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Fig. 7.MMP9 induces enhanced and precocious NCC migration in vivo. Whole mount views or transverse sections of embryos grafted with control (A,C,E,G,I) or MMP9-expressing
RCS cells (B,D,F,H,J). Cell pellets were grafted dorsal to the neural tube at anterior (A,B,E,F,G,H) or posterior (C,D) segmental plate levels. Embryos were incubated for 18 h, and pro-
cessed for HNK1 immunostaining (A–F) or for in situ hybridization with Foxd3 probe (G–J). Transverse sections in (I,J) are taken from dotted lines in (G,H). (K,L): Whole mount
views of embryos injected with control (K) or MMP9-conditioned media (L) and stained for HNK1 6 h later. (M–P): Serial sections taken from control embryos expressing
pCAGGS-IRES-GFP vector (M,O) or pCAGGS-MMP9-IRES-GFP vector (N,P). Embryos were stained with MMP9 (M,N) or HNK1 (O,P) antibodies (red). In (M–P) green represents
electroporated cells, blue represents DAPI stain. Images in O',P' are enlargements of boxed areas in O,P, respectively. In all images, treatments are indicated, grafted cells are marked
with an asterisk, black and white arrows and red arrowheads mark NCC, white arrowheads mark MMP9 expression.
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MMP9-treated explants, regardless of their distance from the neural
tube (Figs. 6O–O″, n=7). Together, these data demonstrate that
MMP9 is indeed sufﬁcient to enhance NCC separation and migration
in ex-vivo explants as evident by the increased areas of migrating NCC
and by their switch from epithelial-to-mesenchymal morphology.
To verify these ﬁndings in whole embryos, control or MMP9-
secreting RCS cells were grafted at, and adjacent to, the dorsal neural
tube of embryos of 16–18 somites, at levels corresponding to theanterior segmental plate (Figs. 7A,B and Table 1). These axial levels
consist of speciﬁed NCC prior to their onset of migration (Cheung et
al., 2005; Sela-Donenfeld and Kalcheim, 1999, 2000, 2002). Embryos
were assessed for NCC migration 18 h later, a stage when NCC are
expected to delaminate from the neural tube into the paraxial meso-
derm. Analysis of HNK1 staining in control embryos revealed typical
migratory patterns of NCC adjacent to the neural tube and at the ros-
tral portion of somites, at the graft levels (Fig. 7A, n=10). Notably,
some HNK1 staining is also located around the graft, indicative for
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massive accumulation of cells expressing HNK1 is found around and
within the MMP9-cell graft (Fig. 7B n=8). Transverse sections were
performed from similarly-treated embryos at the level of the mid-
trunk, followed by HNK1 staining (Figs. 7E,F). In agreement with
the whole-mounted embryos (Figs. 7A,B), NCC were already migrat-
ing in embryos receiving control graft (Fig. 7E). Yet, more HNK1 pos-
itive cells were evident in embryos grafted with MMP9-expressing
cells (Fig. 7F). We next examined whether MMP9 can elicit a preco-
cious delamination of cells at more posterior axial levels, where NCC
are still expected to be conﬁned to the dorsal neural tube at the
time of ﬁxation (Sela-Donenfeld and Kalcheim, 2000). MMP9 or con-
trol cells were implanted at the level of posterior segmental plate and
assessed for HNK1 staining after 14 h, such that the graft will be posi-
tioned adjacent to epithelial somites (Figs. 7C,D). No HNK1 staining
was evident around the control graft, but only at more anterior axial
levels, as expected by this embryonic stage (Fig. 7C n=3). However,
embryos grafted with MMP9 cells showed high levels of HNK1 stain-
ing around the caudal graft (Fig. 7D n=3), further implying that
MMP9 can induce a premature outgrowth of NCC progenitors. Nota-
bly, most of these cells accumulated around the graft, rather than mi-
grating toward the paraxial mesoderm. This may result from the
posterior axial level that may not yet be permissive for NCC migration
or from the premature state of NCC. Next, another set of control or
MMP9-treated embryos was examined for the distribution of Foxd3
(Figs. 7G–J). Embryos grafted with control cells showed Foxd3 distri-
bution in a normal pattern mostly at the dorsal neural tube, as
expected at the time of ﬁxation (Figs. 7G,I n=4). MMP9-grafted em-
bryos showed an increase in Foxd3-expressing cells at, and around,
the dorsal neuroectoderm (Figs. 7H,J n=5).
To further conﬁrm these results we took two additional ap-
proaches; ﬁrst, pCAGGS plasmids encoding for GFP or MMP9-IRES-
GFP cDNAs were electroporated into the neural tubes of 6–8 somite
old embryos. Embryos were analyzed 16 h later for MMP9 expression
and NCC migration. Excess levels of MMP9 protein were clearly dem-
onstrated in the hemi-neural tubes transfected with MMP9 cDNA
(Fig. 7N), in contrast to the contra-lateral side of the neural tube or
to controls (Fig. 7M), which demonstrated normal MMP9 patterns
(see also Fig. 1J). Concomitantly, MMP9-expressing embryos demon-
strated a marked increase in NCC migration (Figs. 7P,P′ n=7), when
compared to control embryos (Figs. 7O,O′ n=8). Furthermore, we
injected conditioned-media (see Fig. 6) into the neural tube lumen
and assessed whether enhancement in NCC migration is rapidly evi-
dent. Embryos of 8 somites were injected twice at the cranial regions
and harvested 6 h later, at the stage of 12 somites, followed by stain-
ing with HNK1 (Figs. 7K,L). Typical migration of NCC was evident in
embryos receiving control media, as expected by the time of ﬁxation
(Fig. 7K n=10). Nevertheless, an increase in HNK1 positive NCC was
observed in embryos receiving MMP9-media (Fig. 7L n=11). This
augmentation was more expanded compared to the grafting method,
as expected by the solubility of this enzyme. Altogether, the results
presented in Fig. 7 and Table 1 indicate by multiple means that excess
MMP9 is sufﬁcient to enhance NCC migration from the neural tube in
vivo.
Mechanism of activity of MMP9 in promoting NCC emigration from the
neural tube
As MMP9 is an enzyme capable of degrading wide range of sub-
strates (Hahn-Dantona et al., 2000), it is tempting to speculate that
at least some of its underlying mechanisms of action in NCC involve
the direct degradation of adhesion molecules, such as N-cadherin
and basal membrane components, such as laminin. Loss of both pro-
teins, from the dorsal neural tube or dorsal basement membrane, re-
spectively, is evident during NCC onset of migration (Duband and
Thiery, 1987; Erickson, 1988; Perris et al., 1989). In order to examinethese possibilities, isolated neural tube explants were cultured for
16 h, to enable normal NCC delamination and migration. Then, condi-
tioned media from control or MMP9-transfected cells were added to
the explants for 0.5 and 3 h, prior to ﬁxation (Figs. 8A–H, n=9 for
each time point). These short incubation periods are expected to re-
ﬂect modiﬁcations in processes such as proteolysis, rather than in
gene expression level and cell differentiation. As expected, there
were no differences in the migration distance between the treat-
ments, since the MMP9 was added only after NCC were already mi-
grated away from the explants (Figs. 8A,C,E,G). Nevertheless, a
remarkable reduction in N-cadherin staining of NCC adjacent and
around the neural rubes was evident already after 30 min of incuba-
tion with MMP9-condition-media (Figs. 8D, D′), while the typical ep-
ithelial N-cadherin staining was observed in NCC adjacent to the
neural tube of control explants (Figs. 8B,B′). The same results were
obtained after 3 h of incubation (Figs. 8F,H). Notably, N-cadherin
was still present within the neural tubes of MMP9-treated explants
(Figs. 8D,H and Fig. 6O), indicating that MMP9 effect on N-cadherin
is most noticeable in NCC. Possible mechanisms for these differential
effects are elaborated in the Discussion section. Intriguingly, we ob-
serve the appearance of ﬂuorescent staining in the explants treated
with MMP9 which are not localized to cell surface but accumulate
in between the cells, or in a dotted fashion around the cell membrane.
These ﬁndings further suggest that MMP9 directly degrades this pro-
tein which may facilitate cell motility. Together, these data suggest
that N-cadherin may be a direct substrate of MMP9 in ex-vivo
explants.
In the next step we aimed to analyze the possible substrates in-
vivo by gain-and-loss-of-function manipulations, in which control
media (Figs. 8I,M,K,O), MMP9-media (Figs. 8J,N) or MMP9 inhibitor
I (Figs. 8L,P) were injected into the neural tube lumen of 5–7
somite-staged embryos, as described in Figs. 4,7. Embryos were incu-
bated for 15 h, ﬁxed, sectioned and immunostained for N-cadherin or
laminin. In agreement with the results obtained in the explants (Figs.
8A–H), N-cadherin expression was decreased from a larger domain of
the dorsal neural tube in MMP9-treated embryos at axial levels where
NCC migration takes place (Figs. 8J–J″ n=6), compared to control
embryos (Figs. 8I–I″ n=6). Notably, expression of N-cadherin that
normally surrounds the entire apical lumen of the neural tube was
also partially-degraded upon the addition of MMP9 (Figs. 8J,J″ com-
pared to I,I″). However, the inhibition of MMP9 revealed no differ-
ences in the region of the dorsal neural tube that lacked N-cadherin
(Figs. 8L,L′ n=8) as compared to control (Figs. 8K,K n=8). These
data suggest that although N-cadherin may be one of the substrates
of MMP9 in vivo (Zheng et al., 2009; Zuo et al., 2011), MMP9 is not
the main enzyme responsible for the degradation of N-cadherin, as
it is still degraded from the dorsal neural tube in MMP9-inhibitory
conditions. Indeed, previous results demonstrated that the Adam pro-
tease is mediating N-cadherin degradation in the dorsal neural tube
(Shoval et al., 2007).
The same experimental setting was used to analyze the ability of
MMP9 to degrade laminin, a major protein of the basal-lamina that
becomes scattered from the dorsal neural tube at stages of NCC mi-
gration, to form a narrow passage for the NCCs (Desban et al., 2006;
Tzu and Marinkovich, 2008). Immunostaining for laminin demon-
strated the typical staining surrounding the neural tube with a gap
at the dorsal part of the neural tube in control embryos (Figs. 8.M,
M',O,O' n=12). A clear widening in the laminin negative region at
the dorsal part of the neural tube was evident upon addition of
MMP9 (Figs. 8 N,N′ n=10). Conversely, the gap in laminin expression
in the dorsal neural tube was not evident when the enzyme was inhib-
ited (Figs. 8P,P′ n=10). These results suggest that MMP9 enhances
breakage of laminin at the basement-membrane to enable NCC emigra-
tion from the neural tube, indicating that laminin is one ofMMP9 native
substrates which its degradation contributes to execute the process of
NCC migration.
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Fig. 8. N-cadherin and laminin are substrates for MMP9 in NCC. (A–H): Bright ﬁeld images (A,C,E,G) and ﬂuorescent images of N-cadherin antibody staining (green; B,D, F, H) of
isolated neural tubes seeded onto ﬁbronectin-coated dishes and grown 16 h, followed by addition of control RCS media (A,B,E,F) or MMP9-containing RCS media (C,D,G,H) for
0.5 h (A,B,C,D) and 3 h (E,F,G,H). Gray circles represent borders of NCC migration area, white lines represent borders of neural tubes. Images in (A′–H′) are enlargements of
boxed areas in (A–H). (I,J,M,N): transverse sections of embryos injected with control (I,M) or MMP9-conditioned media (J,N) as described in Fig. 7. (K,L,O,P): Transverse sections
of embryos injected with control (K,O) or 125 μMMMP9 inhibitor I (L,P) solutions, as described in Fig. 4. Sections were stained with N-cadherin (I–L) or laminin (M–P) antibodies.
Dashed lines mark the gap between N-cadherin expressing areas, yellow arrows indicate N-cadherin positive cells in the NT, and red arrowheads represent the gap in laminin ex-
pression in the basement membrane. Images in I′–P′ are enlargements of marked areas in I–P respectively. In all images, blue represents DAPI stain and treatments are indicated.
NT; neural tube.
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This study asked whether MMP9 is involved in the processes of
NCC detachment from the neural tube and migration. We show
MMP9 mRNA and protein expression at stages and sites where
trunk and cranial NCC delaminate and migrate. Inhibition of MMP9
in NCC by different approaches and at different levels of the neural
axis eliminates NCC delamination and migration, while exogenous
MMP9 enhances and precedes their detachment from the neuroecto-
derm and converts the cell morphology into mesenchyme. Assess-
ment of possible substrates for MMP9 reveals that MMP9 is capable
to cleave both N-cadherin from NCC membranes and laminin from
the basement membrane around the neural tube, acting predomi-
nantly on degrading laminin. Together, these results (summarized
in Table 1) show for the ﬁrst time that MMP9 has a major role in ex-
ecuting the EMT and migration of NCC.
MMP9 is central to many EMT, cell invasion and tissue-remodeling
processes in adults and in cell-culture systems (reviewed in Vu and
Werb, 2000). During embryogenesis, MMP9 serves mainly as a mark-
er in events where ECM remodeling is taking place, such as during an-
giogenesis, heart and limb development (Malemud, 2006a, b; Shelton
and Yutzey, 2007; Simsa et al., 2007a). However, almost nothing was
shown regarding the function for MMP9 during development, al-
though EMT, cell migration and ECM-modiﬁcations constantly
occur. Recent data from Xenopus embryos revealed that MMP9, -7and -18 are expressed in early macrophages and are required for
their migration prior to the establishment of the circulatory system
(Tomlinson et al., 2008). MMP9 was also suggested to be involved
in pancreatic islet formation during the migration of endocrine cells
(Perez et al., 2005), as well as during kidney morphogenesis
(Lelongt et al., 1997). Later in development, MMP9 possibly acts during
odontogenesis,where EMT,motility and active remodeling of the dental
primordia take place (Randall and Hall, 2002). Moreover, during
mandibular arch development, MMP9 was found in the cartilage tis-
sues together with MMP13, where a general inhibition of both
resulted in dramatic defects in Meckel's cartilage (Chin and Werb,
1997; Miettinen et al., 1999; Shimo et al., 2004). Notably, while cra-
nial NCC signiﬁcantly contribute to tooth and mandible formation,
these studies did not examine whether the described defects are
linked to MMP's roles in NCC. Our data shows for the ﬁrst time not
only that MMP9 is expressed in early NCC, but that it has a functional
role in executing their emigration from the neuroectoderm by
degrading laminin, and possibly N-cadherin. MMP9 role in early
NCC stages may very well be conserved also at the later stages of
NCC development. Therefore, future studies are required to assess
the expression and function of MMP9 in later NCC-related structures,
such as in the branchial arches, heart and dorsal root ganglia. In ad-
dition to the NCC themselves, MMP9 was found to be expressed in
their migratory paths. This may implicate that NCC surrounding en-
vironment may also produce MMP9 to promote their migration,
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role in NCC. Yet, MMP9 silencing within NCC was sufﬁcient to pre-
vent their migration, which suggests that a major source of MMP9
production and action resides in NCC.
Intriguingly,MMP9 nullmice are viablewithout any clear embryonic
defect (Vu et al., 1998). These mice exhibit delayed ossiﬁcation of the
post natal growth plate due to inhibition of angiogenesis and apoptosis
in the hypertrophic chondrocytes (Engsig et al., 2000; Sternlicht and
Werb, 2001). In addition,mice lackingMMP9 show reduced tumor inva-
siveness andmetastasis formation, in agreementwith the activity of this
gelatinase in tumor aggressiveness (Coussens et al., 2000; Itoh et al.,
1999). Due to the limited data available regarding MMP9 expression in
embryonic mouse neural tube (Canete-Soler et al., 1995), it is necessary
to examine whether the MMP9 patterns observed in NCC in early avian
embryos are also conserved in mammals, and thus, the lack of any de-
velopmental phenotype in the mutants may be due to redundancy
with other MMPs.
Indeed, previous data have shown thatMMP2 is expressed in chick
NCC within the pharyngeal arch mesenchyme and during their migra-
tion to the heart (Cai et al., 2000), and that MMP2 inhibition pre-
vented cardiac NCC migration (Cai and Brauer, 2002). Another
relevant study (Duong and Erickson, 2004) found MMP2 to be tran-
siently expressed in delaminating NCC at the dorsal neuroectoderm
and that it is rapidly extinguished as they disperse. Conversely, our
data show that MMP9 mRNA and protein are detected in the detach-
ing as well as in the migrating cranial and trunk NCC, suggesting an
ongoing role for MMP9 in this process, in contrast to MMP2 which
is more restricted to the EMT. Further support for this assumption
comes from MMPs inhibition; while application of MMP2-MO pre-
vented EMT but did not affect motility of cells that already delami-
nated from the neural tube (Duong and Erickson, 2004), our
knocking-down of MMP9 activity showed a more robust prevention
of NCC delamination and migration. This effect occurs at several
axial levels, including regions where NCC are still conﬁned to the neural
tube at the time of treatment aswell as domainswhere they are already
undergoing delamination. Notably, some of the chemical inhibitors
used in the previous studies to prevent NCC emigration (Cai and
Brauer, 2002; Cai et al., 2000; Duong and Erickson, 2004), are capable
to inhibit several MMPs, including MMP9, further corroborating our
ﬁndings regarding an important role of MMP9 in NCC. Whether a com-
munal or a single activity of these gelatinases accounts for NCC migra-
tion events in avian embryos is still an open question. Moreover, other
members of the MMP family that have also been identiﬁed in NCC
(MMP14,-16, data not shown) may also contribute to these processes.
Mutations in MMP2 were found in human (Al Aqeel et al., 2000;
Al-Aqeel, 2005; Al-Mayouf et al., 2000; Martignetti et al., 2001).
These mutations manifest a disorder involving characteristic ECM-
degradation pathologies including facial features. MMP2 null mice
(Itoh et al., 1997) are viable, but display several mild defective bone
and cartilage tissues (Mosig et al., 2007), in some agreement with
the human mutation. Notably, cranial defects found in the MMP2
human mutation were also observed in the MMP14-null mice
(Holmbeck et al., 1999). As MMP14 is an activator of MMP2 (Kinoh
et al., 1996; Zhou et al., 2000), it is possible that a deﬁciency in either
of these enzymes can lead to a common pathology. As mentioned
above, our preliminary data suggest that MMP14 is also expressed
in avian NCC, supporting further this possibility. Similar to the unclear
expression or role of MMP9 in mammalian NCC, whether MMP2 is
expressed in mouse NCC is also still elusive (Reponen et al., 1992),
and whether the above mentioned phenotypes result due to NCC de-
fects, is unknown. Based on the previous and our results regarding
MMP2 and MMP9 roles in avian embryos, it is highly plausible that
the lack in clear NCC-related phenotypes in each of the null-mice
models accounts for redundant activity of one gelatinase upon its
missing partner. Characterization of double MMP2–MMP9 mutants
will provide an answer to this possibility.By which precise mechanism(s) MMP9 executes NCC migration?
MMP9 may promote cell migration by degrading ECM molecules
and basement membrane to provide space for cell invasion, as exem-
pliﬁed by MMP9 activity during trophoblast invasion into the mater-
nal decidua (Behrendtsen and Werb, 1997). Support for this activity
comes from our ﬁnding where MMP9 regulated the opening of the
basement membrane by cleaving laminin at sites where NCC delami-
nate from the neural tube. Other studies demonstrated the cleavage
of another basal-membrane component, collagen IV, by MMP9
(Rodriguez et al., 2010). As collagen IV is also missing from the dorsal
neural tube upon NCC migration, similar to laminin (Duband and
Thiery, 1987), it is tempting to speculate that it also serves as a sub-
strate for MMP9, especially since we show that MMP9 is localized to
the same sites.
Another possible mechanism of MMP9 activity on NCC is by break-
ing cell–cell adhesion, enabling EMT and cell separation (Zheng et al.,
2009; Zuo et al., 2011). In agreement with this possibility, we show
that MMP9 is capable to rapidly degrade N-cadherin in vivo and ex-
vivo. Moreover, MMP9, which is a secreted protein, is expressed in re-
gions where N-cadherin is lost from the dorsal neural tube. However,
N-cadherin is still degraded from the dorsal neural tube even when
MMP9 is inhibited. This result indicates that N-cadherin serves as a
substrate for MMP9 in NCC, but is also degraded by several other pro-
teases, such as Adam 10 (Shoval et al., 2007). The orchestrated regu-
lation and activity of these proteases should be further elucidated.
Noticeably, the addition of MMP9 to neural tube explants did not di-
minish N-cadherin from the neural tubes, although it degraded it in
the migratory NCC. This may account for reduced accessibility of
MMP9 to the substrate embedded in the apical membrane of the neu-
ral tube, in contrast to the monolayer sheath of migrating NCC. An-
other possibility may be the production of endogenous inhibitors for
MMP9 by the neural tube cells except from the dorsally-located NC
progenitors. Support for this hypothesis comes from a study where
TIMP2 mRNA is shown to be localized to the apical side of the neural
tune apart from the most-dorsal regions (Cantemir et al., 2004). An
additional attractive explanation may be that, while exogenous
MMP9 is capable to degrade N-cadherin in the entire neural tube,
these cells are constantly synthesizing this protein, resulting in a
balance between the rate of synthesis and degradation. Indeed, some,
but not full degradation is evident in the in vivo injection of MMP9 in
the ventral neural tube. In contrast to neuroepithelial cells, migrating
NCC are known to be prevented from expression of N-cadherin by the
activity of Snail 2 (Cano et al., 2000). Thus, degradation of N-cadherin
from NCC by MMP9 may not be followed by de-novo production of
this adhesion molecule, resulting in its complete loss enabling the sep-
aration and EMTof the cells. Future studieswill be required to assess be-
tween these different possibilities.
Finally, a different mode of action of MMP9 may be by modulating
the activity of biologically-active molecules by direct cleavage, release
from bound stores, or modulation of their inhibitors. For instance,
MMP9 was shown to activate TGF-β by cleaving its latent associated
peptide in tumor cells (Yu and Stamenkovic, 2000). Based on these
examples, it is possible that, in addition to allow separation of cells
and invasion into the ECM, it may modulate signals required for
NCC migration. As BMP signaling is a central determinant in NCC mi-
gration (Sela-Donenfeld and Kalcheim, 1999, 2000), the feasibility of
MMP9 to regulate BMP bioavailability by releasing it from bound pro-
teins or ECM stores, or by cleaving its inhibitor, may result in promoting
NCC delamination.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.ydbio.2012.01.028.
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